Hydroxamic Acids
"Hydroxamic Acids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of weak acids with the general formula R-CONHOH.
Descriptor ID |
D006877
|
MeSH Number(s) |
D02.092.570.394 D02.241.511.372
|
Concept/Terms |
Hydroxamic Acids- Hydroxamic Acids
- Acids, Hydroxamic
- Hydroxamic Acid
- Acid, Hydroxamic
|
Below are MeSH descriptors whose meaning is more general than "Hydroxamic Acids".
Below are MeSH descriptors whose meaning is more specific than "Hydroxamic Acids".
This graph shows the total number of publications written about "Hydroxamic Acids" by people in this website by year, and whether "Hydroxamic Acids" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2007 | 1 | 0 | 1 | 2008 | 0 | 1 | 1 | 2010 | 1 | 0 | 1 | 2018 | 1 | 0 | 1 | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Hydroxamic Acids" by people in Profiles.
-
Peixoto E, Jin S, Thelen K, Biswas A, Richard S, Morleo M, Mansini A, Holtorf S, Carbone F, Pastore N, Ballabio A, Franco B, Gradilone SA. HDAC6-dependent ciliophagy is involved in ciliary loss and cholangiocarcinoma growth in human cells and murine models. Am J Physiol Gastrointest Liver Physiol. 2020 06 01; 318(6):G1022-G1033.
-
Haritwal T, Maan K, Rana P, Parvez S, Singh AK, Khushu S, Agrawala PK. Trichostatin A, an epigenetic modifier, mitigates radiation-induced androphysiological anomalies and metabolite changes in mice as evident from NMR-based metabolomics. Int J Radiat Biol. 2019 04; 95(4):443-451.
-
Pratap J, Akech J, Wixted JJ, Szabo G, Hussain S, McGee-Lawrence ME, Li X, Bedard K, Dhillon RJ, van Wijnen AJ, Stein JL, Stein GS, Westendorf JJ, Lian JB. The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther. 2010 Dec; 9(12):3210-20.
-
Albertus DL, Seder CW, Chen G, Wang X, Hartojo W, Lin L, Silvers A, Thomas DG, Giordano TJ, Chang AC, Orringer MB, Bigbee WL, Chinnaiyan AM, Beer DG. AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma. J Thorac Oncol. 2008 Nov; 3(11):1236-44.
-
Wittwer AJ, Hills RL, Keith RH, Munie GE, Arner EC, Anglin CP, Malfait AM, Tortorella MD. Substrate-dependent inhibition kinetics of an active site-directed inhibitor of ADAMTS-4 (Aggrecanase 1). Biochemistry. 2007 May 29; 46(21):6393-401.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|